· Supplementary figure S1. SNP location and linkage disequilibrium (LD) parameters. · Supplementary figure S2. Meta-analysis of the association between the MCM6-rs3754686 polymorphism and total dairy intake (A), total milk (B), yogurt (C) and cheese (D) in participants (men and women) of the BPRHS, GOLDN, PREDIMED and WHI studies (n=20031). · Supplementary figure S3. Meta-analysis of the association between the MCM6-rs3754686 polymorphism and total dairy intake according to sex in BPRHS, GOLDN, PREDIMED and WHI studies. · Supplementary figure S4. Longitudinal effect of the MCM6-rs3754686 polymorphism on total dairy intake over a 5-y follow-up period in the PREDIMED study in men and women combined. · Supplementary figure S5. Meta-analysis of the association between total milk intake and fasting glucose according to sex in BPRHS, GOLDN, PREDIMED and WHI studies. · Supplementary figure S6. Kaplan Meier curves of cumulative CVD-free survival or mortality-free survival in women depending on the MCM6-rs3754686 polymorphism and dietary intervention group (Mediterranean diet vs control diet) in the PREDIMED participants. · Supplementary figure S7. Kaplan Meier curves of cumulative CVD-free survival or mortality-free survival in women depending on total milk intake in the PREDIMED participants. 
Supplementary figure S6: Kaplan Meier curves of cumulative CVD-free survival or mortality-free survival in women depending on the MCM6-rs3754686 polymorphism and dietary intervention group (Mediterranean diet vs control diet) in the PREDIMED participants. N=4,120 women were analyzed: (A) CVD incidence in the Mediterranean diet group, (B) CVD incidence in the control group,(C) total mortality in the Mediterranean diet group and (D), total mortality in the control group. Multivariable Cox regression models with outcome of CVD incidence or total mortality were fitted as indicated in methods. HR and 95%CI were obtained in the multivariable adjusted models: HR 1 : Model 1 (adjusted for sex, age, field center and dietary intervention group) and HR 2 : Model 2 (adjusted for variables in model 1 plus BMI, diabetes, drinking, smoking, physical activity, medication (hypertension, dyslipemia and glucose) and total energy intake at baseline).
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Supplementary figure S7: Kaplan Meier curves of cumulative CVD-free survival or mortality-free survival in women depending on total milk intake in the PREDIMED participants. N=4,089 women were analyzed: (A) CVD incidence in the Mediterranean diet group, (B) CVD incidence in the control group,(C) total mortality in the Mediterranean diet group and (D), total mortality in the control group. Milk was considered as dichotomous based on the population median: 200 g/d). Multivariable Cox regression models with outcome of CVD incidence or total mortality were fitted as indicated in methods. HR and 95%CI were obtained in the multivariable adjusted models: HR a : Model 1 (adjusted for sex, age, field center and dietary intervention group) and HR b : Model 2 (adjusted for variables in model 1 plus BMI, diabetes, drinking, smoking, physical activity, medication (hypertension, dyslipemia and glucose) and total energy intake at baseline).
Smith CE, et al. 10 Height , m 1.59 ± 0.00 1.58 ± 0.00 1.58 ± 0.01 0.299 1.72 ± 0.01 1.71 ± 0.01 1.71 ± 0.00 0.988 1.60 ± 0.00 1.60 ± 0.00 1.60 ± 0.00 0. : P-values for differences in sex and differences in race. Chi-squared tests were used to test differences in percentages. We used ANOVA test to compare means of continuous variables.
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*: Values are expressed as mean ± standard deviation for continuous variables or as % for categorical variables. The rs3754686 SNP was determined in PREDIMED and imputed in BPRHS. The proxy rs309180 was genotyped in GOLDN and WHI studies.
PREDIMED WHI BPRHS GOLDN
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BPRHS GOLDN PREDIMED
In PREDIMED, some variables (glucose, LDL-C, HDL-C and triglycerides) included missing data point. Biochemical data were available for fasting glucose (n = 2915 participants) total cholesterol (n = 2956 participants), HDL cholesterol (n = 2925 participants), LDL cholesterol (n = 2899 participants), and triglycerides (n = 2946 participants).
*: Values are means ± Standard Error of Mean. The rs3754686 SNP was determined in PREDIMED and imputed in BPRHS. The proxy rs309180 was genotyped in GOLDN and WHI studies.
2: P adjusted for sex, age, field center or ancestry (BPRHS, WHI), family (GOLDN), BMI, smoking, drinking, physical activity, diabetes, medication and total energy intake. Values are means ± Standard Error of Mean. The rs3754686 SNP was determined in PREDIMED and imputed in BPRHS. The proxy rs309180 was genotyped in GOLDN and WHI studies.
1: P adjusted by sex, age, field center or race. 2: P adjusted for sex, age, field center or ancestry (BPRHS, WHI), family (GOLDN), BMI, smoking, drinking, physical activity, diabetes, medication and total energy intake. In PREDIMED, some variables (glucose, LDL-C, HDL-C and triglycerides) included missing data point. Biochemical data were available for fasting glucose (n = 3886 participants) total cholesterol (n = 3964 participants), HDL cholesterol (n = 3912 participants), LDL cholesterol (n = 3883 participants), and triglycerides (n = 3935 participants). **: General Linear Regression models with multivariable adjustment for the indicated covariates were fitted for each population. BPRHS (n = 1232); GOLDN (n = 817); PREDIMED (fasting glucose (n = 3886 participants) total cholesterol (n = 3964 participants), HDL cholesterol (n = 3912 participants), LDL cholesterol (n = 3883 participants), and triglycerides (n = 3935 participants)); W HI (n = 1242). 
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Men n = 2,119
Per variant allele (T)****
Model 1 Model 2
Women n = 2,726
Per variant allele (T)**** Model 4: Model 3 additionally adjusted for total fat and carbohydrates at baseline.
Model 1 Model 2
Total (men + women) n = 4,845
Supplemental table S10. Incidence and hazard ratios (HR) for CVD depending on the MCM6-rs3754686 polymorphism after 4.8 years of median follow-up for the Mediterranean Diet intervention group and stratified by sex
Model 3: Model 2 adjusted for variables in model 2 plus total milk intake.
*: Crude incidence rates were expressed per 1000 person-years of follow-up. **: Codominant model. ***: Recesive model.****: Additive model. We used multivariable Cox regression models with length of follow-up as the primary time variable. Separate models were fitted for CVD and total mortality to estimate the corresponding HRs depending on the model. 
Men n = 946
Model 1 Model 2
Women n = 1,394
Supplemental table S11. Incidence and hazard ratios (HR) for CVD depending on the MCM6-rs3754686 polymorphism after 4.8 years of median follow-up for the Control group and stratified by sex Total (men + women) n = 2,340
*: Crude incidence rates were expressed per 1000 person-years of follow-up. 
Men n = 2,119
Model 1 Model 2
Women n = 2,726
Model 4: Model 3 additionally adjusted for total fat and carbohydrates at baseline.
Model 1 Model 2
Men n = 946
Women n = 1,394
Model 1 Model 2
Total (men + women) n = 2,340
Supplemental table S13. Incidence and hazard ratios (HR) for total mortality depending on the MCM6-rs3754686 polymorphism after 4.8 years of median follow-up for the Control group and stratified by sex
*: Crude incidence rates were expressed per 1000 person-years of follow-up. **: Codominant model. ***: Recesive model.****: Additive model. We used multivariable Cox regression models with length of follow-up as the primary time variable. Separate models were fitted for CVD and total mortality to estimate the corresponding HRs depending on the model. Model 1: Adjusted for sex, age, field center and dietary intervention group. Model 2: Model 1 adjusted for variables in model 1 plus BMI, diabetes, drinking, smoking, physical activity, medication (hypertension, dyslipemia and glucose) and total energy intake at baseline. 
A ) . H e i g h t w a s m e a s u r e d w i t h a S E C A 2 1 4 P o r t a b l e
Stadiometer. Knee height was measured to estimate standing height for participants who were unable to stand. Standing height, knee height, weight, and waist and hip circumferences were measured in duplicate. Other health information was obtained through questionnaires, administered by bilingual interviewers.
In the BPRHS, the MCM6-rs3754686 was imputed. For imputation, the 1000 genome project genotypes were used with reference haplotype panels from the Nov.23 2010 release of the 1000 Genomes project using a MaCH-Admix (http://www.unc.edu/~yunmli/MaCH-A d m i x / ) b y Y u n L i ( U n i v e r s i t y o f N o r t h Carolina of Chapel Hill). The BPRHS dense genotyping data for imputation were obtained using the Affymetrix's Axiom Genome-Wide LAT Array (717,275 autosomal SNPs genotyped). These data were selected to create the input file for MaCH-Admix based on the following quality control criteria: call rate ≥97%, Hardy-Weinberg P-value≥10 -6 , and MAF≥0.05.
Blood sample collection and handling
Blood was collected after a 12 hour fast and was drawn in the home by a certified phlebotomist on the morning following the home interview. A portable centrifuge was used in the home to immediately spin down the blood samples. Blood samples were carried back to the Nutrition Evaluation Laboratory (NEL) at the Human Nutrition Research Center on Aging on the day of collection in coolers equipped with dry ice. Blood samples were immediately cooled to 4°C and the plasma separated within 4 hours in a refrigerated centrifuge. Samples were expected to be online for testing within 1 hour from arrival into laboratory, and were kept cold until analyzed.
Laboratory Quality Control
Biochemical measurements were measured in a state and federal licensed laboratory according to standard operating procedures. Control of pre-analytical variation was maximized through adherence to a manual of operations. Glucose was measured with intra-and inter-assay C.V.s of 2.0% and 3.2% respectively. Total cholesterol was measured by an enzymatic procedure with intra-and inter-assay CVs of 2.0% and 2.8% respectively. Triglycerides were measured by a series of coupled enzymatic reactions with intra-and interassay CVs of 2.0% and 3.4% respectively. HDL was measured by a two-phase reaction with colorimetric endpoint detection, with intra-and inter-assay CVs of 3.0% and 5.0% respectively. 
Study: Genetics of Lipid Lowering Drugs and Diet Network GOLDN
Health Data Collection Genotyping
Weight was taken with minimal clothing on a balance.
Results were recorded to the nearest pound, rounding down. Height was measured while standing as straight as possible without shoes with feet flat on the floor. Height was recorded to the nearest centimeter, rounding down to the nearest centimeter. Clinical and lifestyle questionnaires were administered by a trained interviewer.
F o r t h e G O L D N s t u d y , g e n o t y p e s w e r e obtained using the genome-wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA, www.affymetrix.com). In GOLDN, the proxy SNP MCM6-rs309180, with a high LD with the MCM6-rs3754686 (D'=1 and r 2 =0.95), was genotyped.
Blood sample collection and handling
Blood was collected after a 12 hour overnight fast. Specimens were required to be non-hemolyzed. Blood from visits 1-4 were stored at -70 degrees C at field centers until all visits were complete, and then analysis was performed. For the current study, analyses were performed with blood obtained at visit 2. Blood for glucose and lipids was stored in yellow cap tubes.
Laboratory Quality Control
Quality control procedures were performed quarterly by the Collaborative Studies Clinical Laboratory (CSCL) Minneapolis, Minnesota in conjunction with the CDC. Lipid proficiency specimens (n=36) were distributed by the CDC and assayed by the CSCL in batches at weekly intervals. Acceptable accuracy limits were as follows: total cholesterol: CDC mean ± 3%, triglycerides: <200 = CDC mean ± 8 mg/dL; triglycerides >200= CDC mean ± 5%, HDL-C: CDC mean ± 5% The PREDIMED trial (Prevención con Dieta Mediterránea) was a parallel-group, multicenter, randomized trial. The trial was designed and conducted by the authors, and the protocol was approved by the institutional review boards at all study locations.
Beginning on October 1, 2003, participants were randomly assigned, in a 1:1:1 ratio, to one of three dietary intervention groups: a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with nuts, or a control diet. Randomization was performed centrally by means of a computer-generated random-number sequence. From October 2003 through June 2009, a total of 8713 candidates were screened for eligibility, and 7447 were randomly assigned to one of the three study groups.
Eligible participants were men (55 to 80 years of age) and women (60 to 80 years of age).
Health Data Collection Genotyping
Weight, height, and waist circumference were directly measured. A general medical questionnaire, a 137-item validated food-frequency questionnaire, and the Minnesota Leisure-Time Physical Activity Questionnaire were administered on a yearly basis. Information from the foodfrequency questionnaire was used to calculate intake of energy and nutrients.
The primary end point was a composite of myocardial infarction, stroke, and death from cardiovascular causes. Secondary end points were stroke, myocardial infarction, death from cardiovascular causes, and death from any cause. We used four sources of information to identify end points: repeated contacts with participants, contacts with family physicians, a yearly review of medical records, and consultation of the National Death Index. All medical records related to end points were examined by the end-point adjudication committee, whose members were unaware of the study-group assignments. Only end points that were confirmed by the adjudication committee and that occurred between October 1, 2003, and December 1, 2010, were included in the analyses.
Genomic DNA was extracted from buffy coat. We genotyped the MCM6-rs3754686 polymorphism in all PREDIMED participants with DNA available on a 7900HT Sequence Detection System (Applied Biosystems) by using a fluorescent allelic discrimination TaqMan assay.
Blood sample collection and handling
Blood samples were obtained after an overnight fast and were frozen at −80°C. Fas ng glucose, total cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol were measured by using standard enzymatic methods. In participants whose triglyceride levels were <400 mg/dL, LDL cholesterol concentrations were estimated by using the Friedewald formula. Biochemical measures were available for nearly 7000 participants at baseline.
Laboratory Quality Control
Biochemical analysis was carried out in regional and national licensed laboratories according to standard operating procedures. Control of pre-analytical variation was maximized through adherence to a manual of operations. Glucose was measured with intra-and inter-assay C.V.s of 2.0% and 3.2% respectively. Total cholesterol was measured by an enzymatic procedure with intra-and inter-assay C.V.s of 2.0% and 2.8% respectively. Triglycerides were measured by a series of coupled enzymatic reactions with intra-and interassay C.V.s of 2.0% and 3.4% respectively. HDL was measured by a two-phase reaction with colorimetric endpoint detection, with intra-and inter-assay C.V.s of 3.0% and 5.0% respectively. 
Study: WOMEN'S HEALTH INITIATIVE WHI
Health Data Collection Genotyping
Health information relevant to the current study (such as weight and height) was collected at a clinic visit by trained clinical stuff. Other information, such as age and ethnicity were collected at baseline by self-report. At baseline and the first follow-up clinic visit, which occurred 3 years after baseline, Observational Study participants completed questionnaires on medical, lifestyle and psychosocial characteristics.
F o r t h e W H I S N P H e a l t h A s s o c i a t i o n
Resource (SHARe) study, genotypes were obtained using the genome-wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA, www.affymetrix.com). In WHI, the proxy SNP MCM6-rs309180, with a high LD with the MCM6-rs3754686 (D'=1 and r 2 >0.96), was genotyped.
Blood sample collection and handling
Blood was collected after a 12 hour fast and was maintained at 4 degrees C for up to 1 hour until plasma or serum was separated from cells. Centrifuged aliquots were stored in freezers (at -70 degrees C) within 2 h of collection and sent on dry ice to the central repository, where storage at -70 degrees C was maintained.
Laboratory Quality Control
The accuracy and precision of the lipid assays were regularly monitored with the CDC/NHLBI Lipid Standardization Program to control for any potential drift over time. The CDC/NHLBI Laboratory Quality Assurance and Standardization Program provides the clinical laboratory community with performance guidelines and equipment recommendations that meet the following standards: 1) cholesterol tests with bias from the reference method ≤ 3.0% and a coefficient of variation (CV) ≤ 3.0% 2) HDL cholesterol should be measured with a bias from the reference method ≤ 5% and methods perform with a CV ≤ 4% at ≥ 42 mg/dL (1.09mmol/L) and a standard deviation of ≤ 1.7 mg/dL (0.044 mmol/L) at < 42 mg/dL (1.09 mmol/L) and 3) LDL cholesterol with a bias from the reference method ≤ 4% and perform with a CV ≤ 4%.
